Julie HENRIQUES  is a research engineer in biostatistics. She passed in 2010 a master’s degree in statistical modeling at the University of Franche-Comté. During the master’s degree’s internship in the biostatistics service of the Hospices Civils of Lyon, she realized a  study on the correction of survival estimates in the context of loss to follow-up in HIV cohort .  She worked as independent statistician for 5 years and participated to projects in many area such as financial times series, reservoir computing or EEG signal processing.
 
In 2015, she joined the Methodology and quality of life unit in Oncology (UMQVC) at the University hospital of Besancon.



Latest publications

sample

AbstractBackground: To evaluate the objective response rate (ORR) at 2 months of treatment with regorafenib...

Posted by : Mme. Julie HENRIQUES
Journal name : Cancer Imaging

sample

AbstractSmall bowel adenocarcinoma (SBA) is a rare tumour. We conducted a prospective cohort to describe the prevalence,...

Posted by : Mme. Julie HENRIQUES, Dr. Dewi VERNEREY
Journal name : Int J Cancer

sample

AbstractAnti-EGFR efficacy in patients with microsatellite instability (MSI) metastatic colorectal cancer (mCRC)...

Posted by : Dr. Dewi VERNEREY, Mme. Julie HENRIQUES
Journal name : J Natl Cancer Inst

sample

AbstractBackground: Patients with RAS wild-type (WT) nonresectable metastatic colorectal cancer (mCRC) may receive...

Posted by : Mme. Julie HENRIQUES, Dr. Dewi VERNEREY
Journal name : Oncologist

sample

AbstractIn metastatic pancreatic adenocarcinoma, a high neutrophil-to-lymphocyte ratio (NLR) at diagnosis is a marker of...

Posted by : Dr. Dewi VERNEREY, Mme. Julie HENRIQUES
Journal name : Clin Res Hepatol Gastroenterol

sample

AbstractPurpose: Circulating tumor DNA (ctDNA) has been suggested as a major prognostic factor in resected stage...

Posted by : Mme. Julie HENRIQUES, Dr. Dewi VERNEREY
Journal name : Clin Cancer Res .

sample

AbstractSmall bowel adenocarcinoma (SBA) is a rare tumour. Large genomic analyses with prognostic assessments are...

Posted by : Dr. Dewi VERNEREY, Mme. Julie HENRIQUES
Journal name : Int J Cancer

sample

AbstractBackground: In 2013, the interim analysis of the Protocol for Herceptin as Adjuvant therapy with Reduced...

Posted by : Dr. Sophie PAGET-BAILLY, Mme. Julie HENRIQUES
Journal name : Lancet

sample

AbstractAim: Raltitrexed (RTX) is a thymidylate synthase inhibitor with large pharmacokinetics (PK) variability...

Posted by : Dr. Dewi VERNEREY, Mme. Julie HENRIQUES
Journal name : Br J Clin Pharmacol

sample

AbstractCirculating cell-free DNA (cfDNA) contains circulating tumor DNA (ctDNA), which can be obtained from serial...

Posted by : Mme. Julie HENRIQUES, Dr. Dewi VERNEREY
Journal name : Mol Oncol .

2015-2022 © Copyright - UMQVC.org

Website by Pearlweb